Cheap drug combo could help millions lose weight

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older at the start of treatment * Diagnosis of obesity, defined as body mass index (BMI) ≥ 30 kg/m² * Diagnosis of overweight, defined as BMI ≥ 27 kg/m², associated with at least one metabolic comorbidity, including type 2 diabetes mellitus, prediabetes, dyslipidemia, or arterial hypertension * Patients treated with concomitant sibutramine and topiramate prescribed during routine outpatient medical care * Minimum treatment duration of 3 months * At least two documented outpatient visits, including baseline and follow-up assessments * Availability of clinical and anthropometric data in the medical record, including body weight, BMI, medication dose, treatment duration, and reported adverse events * Treatment performed in an outpatient clinical setting under medical supervision Exclusion Criteria: * Pregnancy or breastfeeding during the treatment period * History of epilepsy or seizures * Severe psychiatric disorders, including schizophrenia, uncontrolled bipolar disorder, or severe depression * Significant cardiovascular disease, including previous myocardial infarction, stroke, transient ischemic attack, significant coronary artery disease, congestive heart failure, clinically relevant arrhythmias, previous deep vein thrombosis, or pulmonary embolism * Uncontrolled arterial hypertension, defined as blood pressure ≥ 160/100 mmHg during follow-up * History of nephrolithiasis * Closed-angle glaucoma or history of increased intraocular pressure associated with medication use * Severe renal or hepatic disease * Concomitant use of medications that may significantly affect body weight, including chronic corticosteroids, atypical antipsychotics, tricyclic antidepressants, other anorectic agents, or other anti-obesity medications * Incomplete medical records lacking sufficient information on body weight, BMI, medication dose, or minimum clinical follow-up * Known hypersensitivity to sibutramine, topiramate, or any component of the formulations * Treatment interruption for more than 1 month associated with weight regain